Department of Pathology, McGill University Health Center, Montreal, Quebec, Canada.
BJU Int. 2010 Aug;106(3):418-23. doi: 10.1111/j.1464-410X.2009.09099.x. Epub 2009 Dec 11.
To evaluate the association between syndecan-1 (CD138) expression and prostate cancer.
We evaluated syndecan-1 expression using a recently constructed tissue microarray of prostatic samples taken from 243 patients, corresponding to 1400 cores, with 69.8%, 5.6%, 17.6% and 7% of the cores representing localized prostate cancer, high-grade prostatic intraepithelial neoplasia, benign prostate tissue and hormone refractory/metastatic disease, respectively.
Metastatic cases had the highest frequency and membranous staining intensity for syndecan-1 overexpression, followed by hormone refractory and localized disease (83.3% vs 34.8% and 25.7%, respectively). There was no significant difference in the frequency of membranous syndecan-1 expression between localized prostate cancer and benign glands (25.7% vs 24.7% of cases, respectively). However, benign glands showed significantly higher intensity staining than localized prostate cancer. We found no significant association between syndecan-1 expression and any of the following: Gleason score, pathological stage, surgical margin status and biochemical recurrence.
The current available evidence, from the present and previous studies, show that syndecan-1 is not an independent predictor of recurrence or tumour-specific survival, diminishing its significance as a clinical marker.
评估硫酸乙酰肝素蛋白聚糖-1（CD138）表达与前列腺癌之间的关系。
我们使用最近构建的 243 例前列腺样本组织微阵列评估硫酸乙酰肝素蛋白聚糖-1 的表达情况，对应 1400 个核心，其中分别有 69.8%、5.6%、17.6%和 7%的核心代表局限性前列腺癌、高级别前列腺上皮内瘤变、良性前列腺组织和激素难治/转移性疾病。
转移性病例的硫酸乙酰肝素蛋白聚糖-1过表达频率和膜染色强度最高，其次是激素难治性和局限性疾病（分别为 83.3%、34.8%和 25.7%）。局限性前列腺癌和良性腺体之间膜性硫酸乙酰肝素蛋白聚糖-1表达的频率无显著差异（分别为 25.7%和 24.7%的病例）。然而，良性腺体的染色强度明显高于局限性前列腺癌。我们发现硫酸乙酰肝素蛋白聚糖-1的表达与以下任何因素均无显著关联：Gleason 评分、病理分期、手术切缘状态和生化复发。
目前的研究证据表明，硫酸乙酰肝素蛋白聚糖-1不是复发或肿瘤特异性生存的独立预测因子，降低了其作为临床标志物的意义。
